In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

The new drug joins UCB’s recently FDA-approved FcRn-targeting antibody Rystiggo (rozanolixizumab), which got the nod from the US regulator in June for gMG patients who are either AChR or anti ...

Last year, the FDA placed a partial clinical hold on tolebrutinib phase 3 trials in MS and myasthenia gravis after cases of drug-induced liver injury were observed, with recruitment of new studies ...

Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the ...